A Phase 2, double-blind, placebo-controlled, randomized,

Project: Research project

Project Details

Description

A Phase 2, double-blind, placebo-controlled, randomized, parallel-group, multicenter study of the efficacy and safety of 40 mg/day KW-6002 as monotherapy in subjects w/PD
StatusFinished
Effective start/end date6/15/0512/15/06

Funding

  • SYNEOS HEALTH, INC

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.